Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11713355 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

Patent 11713355 was granted and assigned to Janssen Biotech on August, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 18 Sep, 2024

"update inverses"

Golden AI

edited on 18 Sep, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 12091466 Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies

Edits on 14 Aug, 2024

"update inverses"

Golden AI

edited on 14 Aug, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 12060432 Combination therapies with anti-CD38 antibodies

Edits on 2 Aug, 2023

"Created via: Entity Importer"

Golden AI

created this topic on 2 Aug, 2023

Edits made to:

Infobox (+40 properties)

Article (+81 characters)

‌

US Patent 11713355 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

Article

The present invention relates to combination therapies with anti-CD38 antibodies.

Infobox

Is a

Patent

Patent Applicant

Janssen Biotech

Current Assignee

Janssen Biotech

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

117133550

Date of Patent

August 1, 2023

Patent Application Number

167415420

Date Filed

January 13, 2020

Patent Citations

‌

US Patent 7183387 Polypeptide variants with altered effector function

‌

US Patent 7223397 Potentiation of anti-CD38-Immunotoxin cytotoxicity

‌

US Patent 7829673 Antibodies against CD38 for treatment of multiple myeloma

‌

US Patent 7829693 Compositions and methods for inhibiting expression of a target gene

‌

US Patent 8008449 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics

‌

US Patent 8088896 Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38

‌

US Patent 8153765 Anti-CD38 antibodies for the treatment of cancer

‌

US Patent 8318154 Super fast-acting insulin compositions

‌

US Patent 8354509 Antibodies to human programmed death receptor PD-1

‌

US Patent 8431380 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

‌

US Patent 9040050 Combination treatment of CD38-expressing tumors

‌

US Patent 9603927 Combination therapies with anti-CD38 antibodies

‌

US Patent 9732154 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

‌

US Patent 10385135 Subcutaneous formulations of anti-CD38 antibodies and their uses

‌

US Patent 10556961 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

‌

US Patent 10604580 Combination therapies with anti-CD38 antibodies

‌

US Patent 10668149 Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors

‌

US Patent 10766965 Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies

‌

US Patent 10781261 Subcutaneous formulations of anti-CD38 antibodies and their uses

‌

US Patent 10793630 Anti-CD38 antibodies for treatment of acute myeloid leukemia

‌

US Patent 10800851 Combination therapies with anti-CD38 antibodies

‌

US Patent 11021543 Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38

‌

US Patent 11566079 Subcutaneous formulations of anti-CD38 antibodies and their uses

‌

US Patent 11618787 Methods of treating high risk multiple myeloma

Patent Primary Examiner

CPC Code

Find more entities like US Patent 11713355 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API